ClinicalTrials.gg
RecruitingNCT07373938Updated Oct 20, 2026

Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus

An observational study in Type 2 Diabetes Mellitus, sponsored by Cardenal Herrera University. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Cardenal Herrera University · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 20, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
80
Ages
40 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.

Planned enrollment
38th of 46
80 · median 842
Started
2026
with 23 others
Observational
46 of 429
9 open now
Primary completion
2026-01
later than 11 of 54 live
Registered
408th of 429
by date

Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 38th largest by planned enrollment of the 46 observational ones that give a count, is one of 24 that started in 2026, is one of 46 observational ones, reaches primary completion later than 11 of the 54 other live ones, and was the 408th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, or all of them as a file.
02

Study summary

This study aims to compare carotid intima-media thickness (CIMT) and layer-specific texture characteristics of the carotid wall between individuals with Type 2 diabetes mellitus (T2DM) and normoglycemic controls, to assess the impact of T2DM on these ultrasound variables and evaluate their ability to discriminate between low and high cardiovascular risk at 10 years.

Read the detailed description

Cardiovascular disease (CVD) is the leading cause of death worldwide and accounts for approximately 45% of all deaths in Europe. Beyond mortality, CVD has a substantial impact on patients' quality of life and represents a significant economic burden on healthcare systems. T2DM is a key cardiovascular risk factor and an important determinant of serious cardiovascular complications, as it is associated with a worse prognosis after cardiac events and almost doubles the risk of all-cause mortality.

Primary prevention of CVD is a cornerstone of nursing practice, especially in the management of chronic diseases such as T2DM, where lifestyle interventions and long-term follow-up are essential. Several tools are available for the early detection of CVD, including cardiovascular risk (CVR) prediction models and imaging techniques. SCORE2 and SCORE2-Diabetes are widely used algorithms for estimating the 10-year risk of major cardiovascular events in European adults. Imaging modalities, such as carotid ultrasound, are becoming increasingly relevant, not only as diagnostic tools but also as support resources in nurse-led clinical assessment, as they provide objective and visual biomarkers of vascular health.

Carotid ultrasound allows for the assessment of established parameters related to CVR, such as CIMT, echogenicity, echovariation, and wall texture. Intima-media thickness (IMT) is a well-recognized marker of arterial injury and cardiovascular risk, especially in people with T2DM. While echogenicity and echovariation reflect tissue composition and structural heterogeneity, they may not detect early microstructural alterations. In contrast, texture features derived from gray-level co-occurrence matrix (GLCM) analyze spatial relationships between pixels, allowing the detection of subtle arterial changes associated with cardiovascular risk. Therefore, in nursing practice, layer-specific carotid texture analysis may offer a more accurate and personalized assessment of cardiovascular risk.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • ultrasound
  • textural analysis
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
40 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

European population aged between 40 and 69 years without known cardiovascular disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • European adults.
  • Age between 40 and 69 years.
  • Confirmed diagnosis of type 2 diabetes mellitus.
  • No established cardiovascular disease.
  • Availability of the required clinical and metabolic variables: Age; Sex; Systolic blood pressure; Non-high-density lipoprotein (non-HDL) cholesterol; Smoking status; Duration of diabetes; (HbA1c); Presence or absence of diabetes-related target organ damage (e.g., albuminuria, retinopathy)

Exclusion criteria

Exclusion Criteria

  • History of clinical cardiovascular disease (secondary prevention).
  • Type 1 diabetes mellitus.
  • Patients with established severe target organ damage or conditions that automatically classify them as very high cardiovascular risk according to ESC guidelines.
  • Advanced chronic kidney disease (estimated \<30 mL/min/1.73 m²).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Type 2 diabetes mellitus

    Diagnostic Test: SCORE2-Diabetes · Diagnostic Test: Ultrasound Assessment

  • Healthy Subjects

    Diagnostic Test: SCORE2 · Diagnostic Test: Ultrasound Assessment

Interventions

  • Diagnostic testSCORE2

    Will classify individuals into four cardiovascular risk categories: * For participants aged 50-69 years: * Low-to-moderate risk: \<5% * High risk: ≥5% to \<10% * Very high risk: ≥10% * For participants aged 40-49 years: * Low-to-moderate risk: \<2.5% * High risk: ≥2.5% to \<7.5% * Very high risk: ≥7.5%

  • Diagnostic testSCORE2-Diabetes

    Will also classify individuals into four risk categories: low (\<5%), moderate (5-10%), high (10-20%), and very high (\>20%).

  • Diagnostic testUltrasound Assessment

    Three bilateral longitudinal scans of the common carotid artery will be obtained for carotid intima-media thickness (CIMT) measurement and stratification of carotid wall layers for subsequent texture analysis. Additionally, a bilateral video recording of the same imaging plane containing a minimum of five cardiac cycles will be acquired. One end-diastolic frame per video-corresponding to the relaxed arterial wall-will be selected to standardize image acquisition and CIMT measurement.

06

What researchers measure

Primary outcomes

  1. SCORE2

    * For participants aged 50-69 years: * Low-to-moderate risk: \<5% * High risk: ≥5% to \<10% * Very high risk: ≥10% * For participants aged 40-49 years: * Low-to-moderate risk: \<2.5% * High risk: ≥2.5% to \<7.5% * Very high risk: ≥7.5%

    Time frame: baseline

  2. SCORE2 - Diabetes

    Low (\<5%), moderate (5-10%), high (10-20%), and very high (\>20%)

    Time frame: baseline

  3. Energy or angular second moment (ASM)

    This measures the uniformity or regularity in the distribution of image values. Higher values indicate greater uniformity in the image

    Time frame: baseline

  4. Homogeneity or inverse difference moment (IDM)

    This reflects the homogeneity of image composition, associated with pixel pairs. Homogeneous images with minimal variations produce high IDM valueS

    Time frame: baseline

  5. Contrast (CON)

    Represents the degree of local variations in grey levels within the image. The greater the variation, the greater the contrast

    Time frame: baseline

  6. Textural correlation (TCOR)

    Expresses linear dependencies between grey levels in the image. Regions with similar grey levels tend to exhibit higher values

    Time frame: baseline

  7. Entropy (ENT)

    This indicates the level of disorder within the image. Homogeneous images result in lower entropy values

    Time frame: baseline

  8. Carotid intima-media thickness (CIMT)

    (mm)

    Time frame: baseline

  9. Echointensity

    The mean pixel intensity within an ultrasound region of interest (related to tissue brightness/echo)

    Time frame: baseline

  10. Echovariation

    The variability or dispersion of pixel intensity within the ultrasound region of interest, corresponding to a measure of tissue heterogeneity

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
  • Francisco Javier Molina Payá
    Elche, Alicante 03204, Spain
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data associated with this paper will be available in the Zenodo repository

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2026 to primary completion in Jan 2026, 0 months.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Mar 2027, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Jan 28, 2026
StartActual
Jan 25, 2026
Primary completionActual
Jan 28, 2026
CompletionEst.
Mar 2, 2027was Aug 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Aug 2, 2026→Mar 2, 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Study completion Aug 2, 2026→Mar 2, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07373938
Responsible party
SERGIO MONTERO NAVARRO (Clinical Professor, Cardenal Herrera University) — Principal investigator
First posted
Jan 28, 2026
Start date
Jan 25, 2026
Primary completion
Jan 28, 2026
Completion
Mar 2, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

SERGIO MONTERO NAVARRO, PhD
Contact
sergio.montero@uchceu.es
+34965426486 ext. 67506
FRANCISCO JAVIER MOLINA PAYÁ, PhD
principal investigator · CEU CARDENAL HERRERA UNIVERSITY

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion